Synergy Pharmaceuticals (NASDAQ:SGYP) : PDUFA Dt: 1/29/17
Oct 26, 2016 22:00:09 GMT
icemandios likes this
Post by Deleted on Oct 26, 2016 22:00:09 GMT
Synergy Pharmaceuticals (NASDAQ:SGYP) which has faded more than 10% in recent trading and currently goes for just over $5.00 a share. However, this biopharma is getting closer and closer to the "finish" line. Its primary drug candidate "plecanatide" has a PDUFA date with the FDA of January 29th for the treatment of Chronic Idiopathic Constipation. The company released long-term safety data for this indication recently, which was more than positive.
This is a significant market which a compound called Linzess dominates and is on the way to being a $1 billion dollar a year drug. Plecanatide in trials showed itself to be slightly faster acting than Linzess. More importantly, it causes less side effects especially the incidents of diarrhea. It should rapidly garner market share if approved.
Phase III trial results should also be out for this compound in the treatment of IBS-C by the end of the year. Approval for that indication could then happen late in the first half of 2017. The median analyst price target on Synergy is currently $13.00 a share.
seekingalpha.com/article/4014557-3-5-biotech-stocks?ifp=0
This is a significant market which a compound called Linzess dominates and is on the way to being a $1 billion dollar a year drug. Plecanatide in trials showed itself to be slightly faster acting than Linzess. More importantly, it causes less side effects especially the incidents of diarrhea. It should rapidly garner market share if approved.
Phase III trial results should also be out for this compound in the treatment of IBS-C by the end of the year. Approval for that indication could then happen late in the first half of 2017. The median analyst price target on Synergy is currently $13.00 a share.
seekingalpha.com/article/4014557-3-5-biotech-stocks?ifp=0